NO20002279L - Sammensetninger av lipidsenkende midler - Google Patents

Sammensetninger av lipidsenkende midler

Info

Publication number
NO20002279L
NO20002279L NO20002279A NO20002279A NO20002279L NO 20002279 L NO20002279 L NO 20002279L NO 20002279 A NO20002279 A NO 20002279A NO 20002279 A NO20002279 A NO 20002279A NO 20002279 L NO20002279 L NO 20002279L
Authority
NO
Norway
Prior art keywords
lipid
lowering agents
compositions
melt
day
Prior art date
Application number
NO20002279A
Other languages
English (en)
Other versions
NO20002279D0 (no
Inventor
Lieven Baert
Geert Verreck
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20002279D0 publication Critical patent/NO20002279D0/no
Publication of NO20002279L publication Critical patent/NO20002279L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Denne oppfinnelsen vedrører nye farmasøytiske sammenset- ninger av lipidsenkende midler som kan administreres til et pattedyr som lider av hyperlipemi, fettsyke eller athe- rosklerose, hvorved en enkel slik doseform kan administre- res en gang om dagen og i tillegg til enhver tid på dagen uavhengig av matinntaket til pattedyret. Disse nye sammen- setningene omfatter partikler som kan oppnås ved å smelte- ekstrudere en blanding som omfatter et lipidsenkende middel og en passende vannløselig polymer og deretter male denne smelteekstruderte blandingen.
NO20002279A 1997-11-03 2000-04-28 Sammensetninger av lipidsenkende midler NO20002279L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97203407 1997-11-03
PCT/EP1998/006998 WO1999022738A1 (en) 1997-11-03 1998-10-27 Compositions of lipid lowering agents

Publications (2)

Publication Number Publication Date
NO20002279D0 NO20002279D0 (no) 2000-04-28
NO20002279L true NO20002279L (no) 2000-04-28

Family

ID=8228898

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002279A NO20002279L (no) 1997-11-03 2000-04-28 Sammensetninger av lipidsenkende midler

Country Status (20)

Country Link
US (1) US6342245B1 (no)
EP (1) EP1028730B1 (no)
JP (1) JP2001521899A (no)
KR (2) KR20010023661A (no)
CN (1) CN1278175A (no)
AR (1) AR013739A1 (no)
AT (1) ATE216238T1 (no)
AU (1) AU746890B2 (no)
BG (1) BG104338A (no)
BR (1) BR9814109A (no)
CA (1) CA2307097A1 (no)
DE (1) DE69804994D1 (no)
EE (1) EE200000186A (no)
HU (1) HUP0004139A3 (no)
NO (1) NO20002279L (no)
NZ (1) NZ503413A (no)
PL (1) PL340305A1 (no)
SK (1) SK5972000A3 (no)
WO (1) WO1999022738A1 (no)
ZA (1) ZA989997B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE444060T1 (de) 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
US20030059487A1 (en) * 2001-09-21 2003-03-27 Niazi Sarfaraz K. Composition and method for the treatment of hypercholesterolemia and hyperlipidemia in mammals
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
NZ546183A (en) * 2003-09-26 2011-04-29 Alza Corp Controlled release formulations exhibiting an ascending rate of release
ATE504288T1 (de) * 2003-09-26 2011-04-15 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
JP5563731B2 (ja) * 2003-09-26 2014-07-30 アルザ・コーポレーシヨン オピオイドおよび非オピオイド鎮痛薬の制御放出製剤
JP4919801B2 (ja) * 2003-09-26 2012-04-18 アルザ・コーポレーシヨン 高い薬剤配合量を提供する薬剤コーティング及びそれを提供する方法
CN101664411A (zh) 2003-11-14 2010-03-10 味之素株式会社 苯丙氨酸衍生物的固体分散体或固体分散体医药制剂
WO2005097131A2 (en) * 2004-04-09 2005-10-20 Janssen Pharmaceutica N.V. Intermittent dosing regimen for the treatment of overweight with mtp-inhibitors
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US20090028938A1 (en) * 2005-08-08 2009-01-29 Abbott Gmbh & Co. Kg Dosage forms with improved bioavailability
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2010143199A1 (en) 2009-06-11 2010-12-16 Suven Nishtaa Pharma Private Limited Solid lipid dispersion for aqueous solubility enhancement of poorly water soluble drugs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO118715B1 (ro) * 1994-10-27 2003-09-30 Janssen Pharmaceutica Nv Inhibitori ai sintezei apolipoproteinei-b
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors

Also Published As

Publication number Publication date
EP1028730A1 (en) 2000-08-23
AU1157699A (en) 1999-05-24
WO1999022738A1 (en) 1999-05-14
NZ503413A (en) 2001-06-29
SK5972000A3 (en) 2000-12-11
KR20010023661A (ko) 2001-03-26
US6342245B1 (en) 2002-01-29
PL340305A1 (en) 2001-01-29
DE69804994D1 (de) 2002-05-23
BR9814109A (pt) 2000-10-03
HUP0004139A3 (en) 2002-03-28
JP2001521899A (ja) 2001-11-13
NO20002279D0 (no) 2000-04-28
BG104338A (en) 2000-12-29
ATE216238T1 (de) 2002-05-15
KR20010023729A (ko) 2001-03-26
EP1028730B1 (en) 2002-04-17
AR013739A1 (es) 2001-01-10
HUP0004139A2 (hu) 2002-02-28
EE200000186A (et) 2001-04-16
CN1278175A (zh) 2000-12-27
AU746890B2 (en) 2002-05-02
CA2307097A1 (en) 1999-05-14
ZA989997B (en) 2000-05-02

Similar Documents

Publication Publication Date Title
NO20002279L (no) Sammensetninger av lipidsenkende midler
Travers et al. Deconjugated bile salts produced by extracellular bile-salt hydrolase-like activities from the probiotic Lactobacillus johnsonii La1 inhibit Giardia duodenalis in vitro growth
Poirier et al. Silver nanoparticles of 70 nm and 20 nm affect differently the biology of human neutrophils
MX9805418A (es) Composiciones fungicidas con biodisponibilidad mejorada.
Enns et al. Early activation and redistribution of calpain activity in skeletal muscle during hindlimb unweighting and reweighting
RU94045855A (ru) Производные пергидроизоиндола, способы их получения и содержащие их фармацевтические композиции
O'Sullivan et al. Bioactivity of bovine lung hydrolysates prepared using papain, pepsin, and Alcalase
AP2002002621A0 (en) Pharmaceutical compositions of glycogen phosphorylase inhibitors
DK1007067T3 (da) Farmaceutiske præparater indeholdende Parthenium integrifolium eller dele deraf eller en ekstrakt bestanddel deraf, anvendelsen af et sådant plantemateriale til fremstilling af ...
ATE521247T1 (de) Eishaltige produkte
Tacheau et al. Vichy Thermal Spring Water (VTSW), a cosmetic ingredient of potential interest in the frame of skin ageing exposome: an in vitro study
Manivannan et al. Diosgenin prevents hepatic oxidative stress, lipid peroxidation and molecular alterations in chronic renal failure rats
Decker et al. Nucleosomes induce lymphocyte necrosis
Kato et al. Environmental pollutant tributyltin promotes Th2 polarization and exacerbates airway inflammation
BR0313711A (pt) Composições lìquidas multi-fases desinfetantes e/ou para limpeza de superfìcies rìgidas
Fernández‐Tomé et al. Lunasin peptide is a modulator of the immune response in the human gastrointestinal tract
Zemanova et al. Roles of gut microbiome in bone homeostasis and its relationship with bone-related diseases
Labat et al. Wheat gluten phenolic acids: occurrence and fate upon mixing
GB2409645A (en) Flower essence-containing medicaments
Grosjean Lysosomal cathepsins of chicken skeletal muscle: distribution and properties
AU5749498A (en) Screw conveyor for the transport of liquid substances and/or lumps of materials
BR9713696A (pt) Sucos de frutas turvos e processos para sua preparação
Thomasson et al. Monovalent concanavalin A
DE69917643T2 (de) Alpha-(2-hydroxyphenyl)nitrone, diese enthaltenden pharmazeutische zubereitungen sowie deren verwendung zur behandlung von entzündungen
Murakami et al. Double Strand Breakage of Chromatin DNA in Cultured Mammalian Cells and DNA Extracted from λ Phage by Aromatic Reductones Derived from Adrenalone

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application